Parkinson's Disease Clinical Trial
— MindPDOfficial title:
Mindfulness-based Intervention for People Affected by Parkinson's Disease: A Distant-delivered Randomised Pilot Trial
Verified date | January 2019 |
Source | City, University of London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Psychological difficulties, especially depression and anxiety are the most prevalent non-motor symptoms in Parkinson's Disease (PD). Pharmacological treatments are not as effective in PD. Mindfulness courses have received increased popularity and recognition as an effective way to manage emotional states, and there is ever growing findings of the effectiveness of mindfulness courses for people with long-term medical conditions. Two small pilot studies have indicated that mindfulness courses can be helpful for people with PD in improving symptoms of depression, language functioning and motor symptoms. The investigators propose to deliver these courses remotely, through Skype video conferences, to make it more accessible for people with mobility limitations and people who live in rural areas.
Status | Completed |
Enrollment | 60 |
Est. completion date | March 2017 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - be diagnosed with PD according to PD Brain Bank criteria by a neurologist or geriatrician - have a computer and internet access at home, since the course will be delivered via Skype - be able to communicate in English fluently - be stabilised on mood altering medication and/or Parkinson's medication for a month Exclusion Criteria: - have severe cognitive impairment that would make participation in the mindfulness sessions and home practice of mindful meditation problematic or distressing. This will be assessed using the Telephone Interview for Cognitive Status-Modified (TICS-M, Brandt et al., 1993). - have severe psychiatric conditions (e.g. psychosis, drug/ alcohol addiction) that can potentially risk failure in the treatment or limit participation in the course - have severe hearing impairment - are currently participating in other psychological therapies - have prior formal training in mindfulness methods or current meditation practice |
Country | Name | City | State |
---|---|---|---|
United Kingdom | City University London | London |
Lead Sponsor | Collaborator |
---|---|
City, University of London |
United Kingdom,
Brandt J, Welsh KA, Breitner JC, Folstein MF, Helms M, Christian JC. Hereditary influences on cognitive functioning in older men. A study of 4000 twin pairs. Arch Neurol. 1993 Jun;50(6):599-603. — View Citation
Cash, T. V., et al. (2015). Pilot Study of a Mindfulness-Based Group Intervention for Individuals with Parkinson's Disease and Their Caregivers. Mindfulness 1-11.
Pickut B, Vanneste S, Hirsch MA, Van Hecke W, Kerckhofs E, Mariën P, Parizel PM, Crosiers D, Cras P. Mindfulness Training among Individuals with Parkinson's Disease: Neurobehavioral Effects. Parkinsons Dis. 2015;2015:816404. doi: 10.1155/2015/816404. Epub 2015 May 26. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Self-Compassion Scale (SCS) | Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20) | ||
Other | Philadelphia Mindfulness Scale (PHLMS) | Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20) | ||
Other | Experiences Questionnaire (EQ) | Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20) | ||
Other | Acceptance Action Questionnaire (AAQ-II) | Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20) | ||
Other | Subjective Well-Being questionnaire (SWB) | Baseline, Post-intervention (week 8) and Follow-up (week 20) | ||
Other | EuroQol Five-Dimensional questionnaire (EQ-5D-3L) | Baseline, Post-intervention (week 8) and Follow-up (week 20) | ||
Other | Visual Analogue Scale (VAS) | Baseline, Post-intervention (week 8) and Follow-up (week 20) | ||
Other | ICEpop CAPability measure for Adults (ICECAP-A) | Baseline, Post-intervention (week 8) and Follow-up (week 20) | ||
Other | Adult Social Care Outcomes Toolkit (ASCOT) | Baseline, Post-intervention (week 8) and Follow-up (week 20) | ||
Primary | Change from baseline Hospital Anxiety and Depression Scale (HADS) at 4, 8 and 20 weeks | HADS also assessed at Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20) time points. | Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20). | |
Secondary | Parkinson's Disease Activities of Daily Living Scale (PADLS) | Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20) | ||
Secondary | Brief Pain Inventory (BPI) | Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20) | ||
Secondary | Fatigue Severity Scale (FSS) | Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20) | ||
Secondary | Insomnia Severity Index (ISI) | Baseline, Mid-intervention (week 4), Post-intervention (week 8) and Follow-up (week 20) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Terminated |
NCT02894567 -
Evaluation of Directional Recording and Stimulation Using spiderSTN
|
N/A | |
Completed |
NCT02939391 -
A Study of KW-6356 in Subjects With Early Parkinson's Disease
|
Phase 2 |